ClinicalTrials.gg
CompletedNCT01814228Updated Apr 27, 2020

Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope

An interventional study of transcatheter ablation of ganglionated plexi in right atrium in Neuromediated Cardioinhibitory Syncope, sponsored by Policlinico Casilino ASL RMB. Completed at 1 site in Italy. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-04-27.

Sponsored by Policlinico Casilino ASL RMB · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Syncope with a site in Italy — 4 open to participants now, 5 under way, none of them phase 3. Syncope · Italy.

Enrollment
14th of 14
20 · median 119
Started
2013
the only one that year
No phase
9 of 36
none open now
Registered
8th of 36
by date

Among the 36 studies in Syncope with a site in Italy, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2013, is one of 9 with no phase, and was the 8th registered.

Syncope

202 studies on the registry are indexed under Syncope; 37 are open to participants now.

Browse Syncope studies →

Open to participants now

4 of the 36 studies in Syncope with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 26 Syncope studies recruiting now, 17 (65%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Syncope with a site in Italy, or all of them as a file.
02

Study summary

Cardioinhibitory neurocardiogenic syncope (CNS) or vasovagal syncope, is the most frequent aetiology of syncope in young people without apparent cardiac or neurological pathology. It is usually caused by inappropriately trigger-activated cardiac reflex which finally precipitates asystole, sinus bradycardia, or atrioventricular (AV) block [1]. Despite young patients affected by CNS have an excellent prognosis when electro-structural heart diseases are excluded [2], their quality of life may be seriously affected by recurrent episodes [2, 3]. Cardiac pacing might help to control symptoms and therefore is considered in patients aged more than 40 years old with recurrent episodes and documented cardioinhibitory response [1, 4]. In young individuals, the role of cardiac pacing is dubious due to predicted frequent device substitutions and adverse ventricular remodeling over time. Recently, radiofrequency (RF) biatrial ablation of ganglionated plexi (GP) has showed promising results in the short and long-term treatment of reflex syncope, functional atrioventricular block, or sinus node dysfunction [5, 6]. Nonetheless, strong evidences are emerging about efficacy of transcatheter ablation limited to ganglionated plexi in the right atrium with the possibility to avoid side-effects related to left-sided procedures [6]

Aim of study

To evaluate in a large cohort of patients effectiveness and safety of gangliar transcatheter ablation in the right atrium to obtain atrial denervation and prevent CNS.

Study population and methods

Twenty consecutive patients affected by cardioinhibitory neurocardiogenic syncope will be enrolled in the study.

Inclusion criteria:

  • age between 18 and 60 years
  • 3 syncopal episodes at least of likely CNS in the previous 2 years
  • marked cardioinhibitory response to HUT or documented asystolic pauses at internal loop recorder registration [7].

Cardioinhibition will be considered as elicitation of asystolic pause (sinus arrest or AV block) ≥ 3 seconds associated to syncope or ≥ 6 seconds and related presyncope.

Exclusion criteria:

  • documented myocardial and/or valvular abnormalities on 2D echocardiogram (ejection fraction lower than 50%)
  • documented tachyarrhythmias as possible causes of symptoms
  • channelopathies (Brugada syndrome, LQT or SQT syndrome)
  • ventricular preexcitation
  • symptomatic orthostatic hypotension diagnosed by standing blood pressure measurement
  • pregnancy in women
  • previous cardiac pacemaker implantation.

After obtaining informed consent patients will undergo to basal electrophysiological study (EPS) to record AH interval, HV interval, Wenckebach cycle length, sinus node recovery time (SNRT) and correct sinus node recovery time (cSNRT); the same parameters will be recorded immediately after ablation. Following basal EPS an accurate (200 valid points at least) electroanatomic right atrium mapping (CARTO 3™ Biosense Webster, Inc) will be performed and subsequently radiofrequency delivered at right atrial anatomic sites where the underlying presence of ganglionated plexi (GPs) clusters was regarded as highly probable, on the basis of anatomical studies [8-11]: the supero-posterior area (superior right atrial GP, adjacent to the junction of the superior vena cava and the posterior surface of RA), the middleposterior area (posterior right atrial GP, posterior surface of the RA adjacent the interatrial groove), the infero-posterior area (inferior right GP placed between the inferior vena cava, coronary sinus ostium, and near the atrioventricular groove). Transcatheter ablation will be performed using an 8mm-tip catheter (Biosence-Webster Navistar DS 8mm) or an irrigated 4 mm-tip catheter with force control system (Biosence Webster Smarttouch). Ablation will be performed until complete elimination of local atrial electrical activity. Response to radiofrequencies delivery will be considered successful in case of asystolic pause or cardiac cycle lengthening of 30% (compared to basal cycle) at least. To prolong RF delivery despite asystolic response, a quadripolar catheter will be positioned in right ventricle to backup stimulation. To avoid phrenic nerve injury, high amplitude stimulation will be performed just before radiofrequency delivery to the superior right atrial GP.

HRV analysis will be performed on admission, at 2 hour after ablation and patients discharge. The HRV analysis will include the following parameters: mean, maximal and minimal heart rate, SDNN (standard deviation of Normal-Normal), RMSSD (root mean square successive difference), pNN50 (percentage of differences between adjacent N-N intervals that are >50 msec), LF (low frequency), HF (high frequency).

Moreover, an HUT and an HRV analysis will be performed at 1, 3, 6 and 12 months after ablation procedure during the follow up.

03

Conditions studied

  • Neuromediated Cardioinhibitory Syncope

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Twenty consecutive patients affected by cardioinhibitory neurocardiogenic syncope will be enrolled in the study.

Inclusion criteria

Inclusion criteria:

  • age between 18 and 60 years
  • 3 syncopal episodes at least of likely CNS in the previous 2 years
  • marked cardioinhibitory response to HUT or documented asystolic pauses at internal loop recorder registration [7].

Cardioinhibition will be considered as elicitation of asystolic pause (sinus arrest or AV block) ≥ 3 seconds associated to syncope or ≥ 6 seconds and related presyncope.

Exclusion criteria

Exclusion criteria:

  • documented myocardial and/or valvular abnormalities on 2D echocardiogram ( lower than 50%)
  • documented tachyarrhythmias as possible causes of symptoms
  • channelopathies (Brugada syndrome, LQT or SQT syndrome)
  • ventricular preexcitation
  • symptomatic orthostatic hypotension diagnosed by standing blood pressure measurement
  • pregnancy in women
  • previous cardiac pacemaker implantation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    right atrium ganglionated plexi transcatheter ablation

    right atrium ganglionated plexi transcatheter ablation

    Procedure: transcatheter ablation of ganglionated plexi in right atrium

Interventions

  • Proceduretranscatheter ablation of ganglionated plexi in right atrium
06

What researchers measure

Primary outcomes

  1. neuromediated cardioinhibitory syncope recurrence

    Time frame: 1 year

07

Study locations

1 site
  • Policlinico Casilino
    Rome, Lazio 00169, Italy
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Apr 2020 and a completion of Apr 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2013
First posted
Mar 19, 2013
Start
Sep 2013
Primary completionActual
Apr 2020
CompletionActual
Apr 2020
Last update
Apr 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01814228
Lead sponsor
Policlinico Casilino ASL RMB
Responsible party
Leonardo Calò, MD (MD, FESC, Policlinico Casilino ASL RMB) — Principal investigator
First posted
Mar 19, 2013
Start date
Sep 2013
Primary completion
Apr 2020
Completion
Apr 2020
Last update
Apr 27, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion